These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 28552213)

  • 1. Pricing increases for cancer drugs sparks investigation.
    Venkatesan P
    Lancet Oncol; 2017 Jul; 18(7):e372. PubMed ID: 28552213
    [No Abstract]   [Full Text] [Related]  

  • 2. Having "Skin in the Game" and Allowing Cross-Border Importation of Drugs to Lower High Prices of Cancer Drugs.
    Kantarjian H; Mathisen MS; Lipton JH
    JAMA Oncol; 2015 Sep; 1(6):729-30. PubMed ID: 26182331
    [No Abstract]   [Full Text] [Related]  

  • 3. US trade rep is pressing Indian government to forbid production of generic cancer drug, consortium says.
    Cohen D
    BMJ; 2014 Nov; 349():g6593. PubMed ID: 25370846
    [No Abstract]   [Full Text] [Related]  

  • 4. Drugs are scarce as mix of programs aims to ease access.
    Brower V
    J Natl Cancer Inst; 2009 Oct; 101(19):1304-6. PubMed ID: 19755680
    [No Abstract]   [Full Text] [Related]  

  • 5. An Oncologist's Letter to Santa: Bring Me Drugs!
    Tempero M
    J Natl Compr Canc Netw; 2018 Dec; 16(12):1411. PubMed ID: 30545986
    [No Abstract]   [Full Text] [Related]  

  • 6. Selling Patents to Indian Tribes to Delay the Market Entry of Generic Drugs.
    Ablavsky G; Larrimore Ouellette L
    JAMA Intern Med; 2018 Feb; 178(2):179-180. PubMed ID: 29297039
    [No Abstract]   [Full Text] [Related]  

  • 7. Folly or volley? Will a dollar $4 pill finally open the healthcare market to competitive pricing?
    Sturm AC
    Healthc Financ Manage; 2006 Nov; 60(11):120-2. PubMed ID: 17094287
    [No Abstract]   [Full Text] [Related]  

  • 8. Long way down--pharmaceutical companies fear falling off 'patent cliff'.
    Sklan A
    Pharm Pat Anal; 2012 Jul; 1(3):240. PubMed ID: 24386667
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmaceuticals and Medical Devices: Business Practices.
    Steiner DJ;
    Issue Brief Health Policy Track Serv; 2016 Dec; 2016():1-38. PubMed ID: 28252886
    [No Abstract]   [Full Text] [Related]  

  • 10. The London Agreement and the future of parallel imports.
    Muir J
    Nat Biotechnol; 2008 Aug; 26(8):877-9. PubMed ID: 18688237
    [No Abstract]   [Full Text] [Related]  

  • 11. Competition and the Reference Pricing Scheme for pharmaceuticals.
    Ghislandi S
    J Health Econ; 2011 Dec; 30(6):1137-49. PubMed ID: 21937137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmaceuticals and medical devices: business practices.
    Steiner DJ
    Issue Brief Health Policy Track Serv; 2013 Dec; ():1-36. PubMed ID: 24482889
    [No Abstract]   [Full Text] [Related]  

  • 13. The ethics and economics of pharmaceutical pricing.
    Parker-Lue S; Santoro M; Koski G
    Annu Rev Pharmacol Toxicol; 2015; 55():191-206. PubMed ID: 25149920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A "Method of Use" to Prevent Generic and Biosimilar Market Entry.
    Tu SS; Sarpatwari A
    N Engl J Med; 2023 Feb; 388(6):483-485. PubMed ID: 36734878
    [No Abstract]   [Full Text] [Related]  

  • 15. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.
    Experts in Chronic Myeloid Leukemia
    Blood; 2013 May; 121(22):4439-42. PubMed ID: 23620577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer drug prices and the free-market forces.
    Kantarjian H; Zwelling L
    Cancer; 2013 Nov; 119(22):3903-5. PubMed ID: 24037953
    [No Abstract]   [Full Text] [Related]  

  • 17. Pricing Cancer Drugs: When Does Pricing Become Profiteering?
    Kushnick HL
    AMA J Ethics; 2015 Aug; 17(8):750-3. PubMed ID: 26270874
    [No Abstract]   [Full Text] [Related]  

  • 18. Biosimilar and generic cancer drugs unlikely to bend cost curve in the USA.
    Bennett CL; Sartor OA; Armitage JO; Kantarjian H
    Lancet Oncol; 2017 Jan; 18(1):22-23. PubMed ID: 28049571
    [No Abstract]   [Full Text] [Related]  

  • 19. [Free trade agreements make the drugs more expensive].
    Jeppsson A
    Lakartidningen; 2009 Nov 18-24; 106(47):3181. PubMed ID: 20082499
    [No Abstract]   [Full Text] [Related]  

  • 20. Market spiral pricing of cancer drugs.
    Light DW; Kantarjian H
    Cancer; 2013 Nov; 119(22):3900-2. PubMed ID: 24002792
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.